Island Pharmaceuticals Ltd. announced that Institutional Review Board approval has been granted for the ISLA-101 Phase 2a PEACH 1 clinical trial, to be undertaken at SUNY Upstate University in New York. The PEACH study is a Phase 2a Randomized, Double Blind, Placebo-controlled Study for the Prophylactic Examination of an Antiviral in a Dengue Challenge model. Institutional Review Board approval in the United States is analogous to Human Research Ethics Committee (HREC) approval in Australia.

It is an important regulatory requirement, necessary for trial commencement. The approval has been provided, pending clearance of Island's Investigational New Drug (IND) application by the United States Food and Drug Administration. The IND is currently in the final stage of completion and is expected to be filed in December 2022.